11/13/2025
Dr. Jennifer Green delivered an outstanding update on incretin-based therapeutics, covering GLP-1 RAs, dual GIP/GLP-1 agents, and new oral options transforming cardio-kidney-metabolic care.
Session Highlights:
✅ Broad Benefits: GLP-1 receptors extend beyond the pancreas—supporting heart, kidney, immune, and metabolic health.
✅ Strong CKM Protection: Major trials (STEP-HFpEF, FLOW, SELECT, SOUL) show improvements in HF symptoms, weight, CKD progression, and reduced MACE—even in non-diabetic patients.
✅ Obesity + Metabolic Impact: Next-gen incretins deliver leading weight loss (up to 20–22% with tirzepatide) and support chronic obesity management.
✅ New Indications Emerging: Evidence shows benefits in OSA, MASH, and metabolic liver disease.
✅ Safety & Access: GI effects manageable with slow titration; semaglutide/tirzepatide shortages resolved; generics improving access.
✅ What’s Next: Powerful agents in development (retatrutide, survodutide, AMG-133, orforglipron) and major outcome trials underway.
Incretin therapies are rapidly evolving—and today’s session showed just how transformative they are for diabetes, obesity, heart failure, and metabolic liver disease. Thank you Dr. Green!